News and Trends 12 Dec 2022 OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for the treatment of B- and T-Cell acute lymphoblastic leukemia (B- and T-ALL). The information was provided at the American Society of Hematology (ASH) annual meeting in New Orleans, Louisiana. The preclinical data on OSE-127 presented […] December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published OSE Immunotherapeutics SA has announced the publication of data in the peer-reviewed journal Science Advances on a first-in-class preclinical program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy. The academic collaboration conducted with Elise Chiffoleau’s team at the Center for Translational Research in Transplantation and Immunology has led to identify CLEC-1 as […] November 23, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial Servier and French biotech company OSE Immunotherapeutics SA have completed patient enrollment in a phase 2a clinical trial evaluating the efficacy and safety of monoclonal antibody OSE-127/S95011 in primary Sjögren’s syndrome. The international, randomized, double-blind, placebo-controlled, phase 2a study is designed to evaluate the efficacy and tolerance of the monoclonal antibody OSE-127/S95011 in primary Sjögren’s […] November 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 6 Jul 2020 How Immuno-Oncology Contributes to the Fight Against Covid-19 As the Covid-19 pandemic sweeps the world, cancer research is proving a valuable resource for developing new treatments for infectious diseases by harnessing the power of the immune system. Despite the growing number of viral outbreaks of different sizes and severity we have observed in the past years, the infectious disease market is far behind […] July 6, 2020 - 7 minutesmins - By Maya Chergova Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2020 French Partnership Deploys AI for Antibody Drug Discovery French companies OSE Immunotherapeutics and MAbSilico are teaming up to drive the discovery of new antibody drugs using artificial intelligence. The three-year partnership will use artificial intelligence, or AI, in six programs designed to accelerate the development of therapeutic monoclonal antibodies (mAbs) that can target cancer and autoimmune diseases. AI can improve the efficiency of […] February 13, 2020 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 May 2019 The Top 20 Women in Leading Biotech Roles in Europe The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way to go to achieve ideal levels of equality, there are more and more women filling leading roles in companies across Europe. Here are 20 women making an impact in the European biotech industry. Diversity comes […] May 21, 2019 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2019 Artificial Intelligence Could Beat Tumors Resistant to Immunotherapy The French company OSE Immunotherapeutics has signed a partnership to use artificial intelligence to develop treatments for tumors that don’t respond to checkpoint inhibitor drugs. In the last five years, checkpoint inhibitor drugs have become a potentially life-saving option for people that don’t respond to traditional cancer treatments. These antibody drugs have shown promise in […] March 27, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2018 Boehringer Offers €1Bn for New Checkpoint Inhibitor from a French Biotech OSE Immunotherapeutics could receive up to €1.1Bn from its new partner Boehringer Ingelheim, which has set its eyes on a new type of checkpoint inhibitor being developed by the French biotech. OSE Immunotherapeutics has entered a global license and collaboration deal with Boehringer Ingelheim for the development of OSE-172, a checkpoint inhibitor antibody to treat […] April 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Mar 2018 Say Hello to the Top 14 Entrepreneurial Women in European Biotech Today, March 8, is international women’s day. To celebrate the achievements of women we’re revisiting our list of the women that have founded some of the hottest biotechs in Europe. Once upon a time, you would have been hard pushed to find a woman in a senior position at a top biotech – now, they […] March 8, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2017 Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance OSE Immunotherapeutics has successfully completed the necessary milestones to bring a treatment for autoimmune disease to the clinic, triggering a milestone payment from its partner Bpifrance. OSE Immunotherapeutics, based in Nantes, France, has received €2.6M from the French public investment agency Bpifrance after completing another milestone in the development of a therapy for inflammatory bowel disease. […] June 22, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2017 French Biotech Enters New Agreement to Advance its IBD Immunotherapy OSE Immunotherapeutics has teamed up with Selexis in a new license agreement to support the development of its IL-7 antagonist for the treatment of IBD. In the end of last year, French OSE Immunotherapeutics joined forces with Servier to develop and commercialize its interleukin-7 antagonist (Effi-7) in a deal that could earn the biotech up […] May 24, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2016 Catching Up with the French Leader in Immuno-Oncology #BIOEurope Despite the deflating attitudes towards immuno-oncology, OSE Immunotherapeutics is forging ahead. We caught up with the CEO, Dominique Costantini, at BIO Europe to make our first video Interview. OSE Immunotherapeutics is developing immunotherapy products against invasive and metastatic late-stage cancers. Memopi is one of its key technologies, and it is currently under development for ovarian, colon and breast […] November 7, 2016 - 1 minutemin - By Philip Hemme Share WhatsApp Twitter Linkedin Email